Engflag

Etodol

Quick links to important sections

Etodol

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etodol

What is Etodol? A Factual Overview

Property Description
Active Ingredient Etodolac (INN)
Form Tablets, Capsules, Extended-Release Tablets
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Pain relief, reduction of inflammation and fever
Origin Synthetic, Pyranocarboxylic Acid Derivative

What is Etodol and What is its Classification?

Etodol is a medicine containing the synthetic active compound Etodolac. It is definitively classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), belonging to the chemical subgroup of pyranocarboxylic acid derivatives. This classification establishes its general therapeutic purpose: providing symptomatic relief from physical discomfort driven by inflammation, pain, and fever. Etodolac is used to reduce swelling and pain, noting that it acts by preventing the body from producing certain substances that cause inflammation. This means the medication helps ease discomfort by targeting the underlying biological processes that cause symptoms.

Composition, Structure, and Preparation

The active substance Etodolac (INN) is prepared for oral intake, with pharmaceutical preparations including standard tablets, capsules, and formulations for extended-release tablets. Chemically, Etodolac is a racemic mixture, where the pharmacological effect is primarily attributed to the (+)S-enantiomer. As a single active entity product, its composition is defined by the Etodolac compound and necessary solid oral excipients required for the manufactured dosage form. The drug is often prescribed for adult patients managing chronic inflammation, a typical use scenario for this class of NSAIDs.

What is the General Benefit of Etodolac?

The general benefit of Etodolac stems from its primary action: inhibiting the body's synthesis of prostaglandins, the biological mediators responsible for transmitting pain signals and initiating swelling. Etodolac is notable because it operates as a preferential cyclooxygenase-2 (COX-2) inhibitor, showing a greater tendency to block the COX-2 enzyme, which is highly active during inflammation. This distinction in enzyme targeting has been clinically recognized for its role in modulating the inflammatory response compared to non-selective NSAIDs. This selective inhibition facilitates the reduction of swelling and general tenderness, leading to effective overall symptomatic management of pain and physical discomfort.

Regulatory References

  1. MedlinePlus, National Institutes of Health

What side effects are possible with Etodol?

Possible Side Effects and Safety Information

The safety profile of Etodolac, the active ingredient in Etodol, is detailed in official regulatory documents and organized by the physiological system affected and the frequency of occurrence.

Adverse reactions classified as Common in official labeling often affect the Gastrointestinal System, including symptoms such as abdominal pain, nausea, dyspepsia (indigestion), diarrhea, and flatulence. Effects on the Nervous System that are commonly documented include headache, dizziness, and fatigue.

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the potential for Serious Adverse Reactions, which can occur without prior symptoms and can be fatal. These include:

  • Cardiovascular Thrombotic Events: Documented risk of events such as myocardial infarction and stroke. This risk may occur early in treatment and is noted to increase with the duration of use.
  • Gastrointestinal Adverse Events: Potential for bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during the treatment period.

The official documentation highlights safety considerations for specific groups. Older adults are identified as a population at a greater risk for developing serious gastrointestinal and cardiovascular events. The drug is generally contraindicated for the management of pain following Coronary Artery Bypass Graft (CABG) surgery and is also contraindicated in later stages of pregnancy.

Overdose and Emergency Response

The official regulatory documentation for Etodolac describes the manifestations and required response in cases of acute ingestion exceeding the recommended dose. Overdose may initially present with common signs such as drowsiness, lethargy, nausea, vomiting, and epigastric pain. A documented complication is the potential for gastrointestinal bleeding, which may be indicated by bloody, black, or tarry stools, or vomit resembling coffee grounds.

While most NSAID overdoses are managed supportively, severe and life-threatening outcomes have been formally documented. These rare manifestations include coma (loss of consciousness), acute renal failure, respiratory depression, and hypertension. Older patients are noted to have an increased risk for severe gastrointestinal adverse events.

Immediate actions are officially mandated. Any suspected overdose requires seeking immediate medical attention. Regulators state that emergency services must be called immediately if the person exhibits severe, life-threatening symptoms such as a seizure, trouble breathing, or the inability to be awakened. Management is officially defined as symptomatic and supportive treatment, with no specific antidote documented. Procedures such as gastric lavage and administration of activated charcoal may be utilized as part of this management.

Therapeutic Uses of Etodol

What Etodol Treats: Main Uses and Benefits

Etodolac is a medicine generally used to support symptomatic relief by moderating symptoms across therapeutic domains involving inflammatory or irritative states and physical discomfort. It is applied in contexts where additional symptomatic support is needed and can help patients cope more steadily with difficult or disruptive episodes.

The medication is commonly used to help with pain, tenderness, swelling, and stiffness associated with arthritis. The main conditions for which Etodolac provides symptomatic management include Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). Furthermore, it is relevant for easing acute pain in conditions like tendinitis, bursitis, and gouty arthritis flare-ups, and is frequently applied for temporary relief following medical or dental procedures.

The medication is used to relieve pain, tenderness, swelling, and stiffness caused by arthritis.

Management of Symptoms and Patient Benefit

This domain focuses on helping patients manage the symptom clusters that appear over time, particularly the persistent joint pain, swelling, and stiffness that creates noticeable physiological strain, which may interfere with daily functioning. The benefit contributes to improved day-to-day comfort and contributes to supportive relief when symptoms interfere with routine activities during chronic disease. For acute scenarios, the benefit is relevant for easing the overall symptom load, which may temporarily be overwhelming, and assists with maintaining functional stability during challenging symptomatic phases.

Quick Fact: Symptomatic Support for Discomfort
Common Use: Is commonly used for symptomatic management of pain and inflammation associated with OA, RA, and JRA.
Acute Support: May assist with short-term support for pain from musculoskeletal injuries and post-procedural discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Etodolac (Etodol) — Official Regulatory Information

The eligibility profile for Etodolac is strictly defined by official contraindications and population restrictions found in government regulatory labeling.

Eligibility Scope Status
Contraindicated Populations Prohibited in patients with a history of aspirin or NSAID-induced allergic reactions, after Coronary Artery Bypass Graft (CABG) surgery, and during the third trimester of pregnancy (after 30 weeks). Use is also prohibited in advanced renal disease and severe heart failure.
Age-Related Eligibility Adults are approved for general use. Pediatric use (under 18 for conventional forms, under 6 for extended-release) is not established due to insufficient data. The extended-release form is approved for Juvenile Rheumatoid Arthritis in children 6 to 16 years.
Conditional Restrictions Caution and monitoring are required for elderly patients and for those with mild-to-moderate renal or hepatic dysfunction. Patients with a history of GI ulcers/bleeding or cardiovascular risk factors must be closely monitored.
Reproductive Status Contraindicated in the third trimester of pregnancy. Use is not recommended during breastfeeding or for women attempting to conceive.

This structure strictly separates eligibility status (Prohibited, Caution, Not Established) from non-eligibility groups, adhering to the regulatory classification.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific patterns of interaction for Etodolac, primarily involving altered drug exposure or pharmacodynamic interference with co-administered agents.

Documented Pharmacokinetic and Exposure Effects

Interacting Agent Official Regulatory Outcome
Lithium Reduces renal clearance, leading to elevated plasma levels and increased toxicity.
Phenylbutazone Increases the free (unbound) fraction of Etodolac by approximately 80%.
Methotrexate Co-administration may enhance the toxicity of Methotrexate due to reduced elimination.
Digoxin / Cyclosporine May elevate serum levels and increase the potential for toxicity of these drugs.

Pharmacodynamic Interference and Contraindications

The profile includes interference with agents that regulate blood pressure or fluid balance. Etodolac may diminish the antihypertensive effect of ACE-inhibitors and Angiotensin Receptor Blockers (ARBs), and can reduce the water-losing effect of Furosemide and Thiazide diuretics. When taken with Oral Anticoagulants (e.g., Warfarin), there is a synergistic increase in the risk of serious gastrointestinal bleeding.

Use with other NSAIDs or non-low-dose Aspirin is generally not recommended. Etodolac is formally contraindicated for treating peri-operative pain associated with CABG surgery. A mandatory timing restriction is noted: use is prohibited for 8–12 days following Mifepristone administration.

Substance and Population Notes

The official profile notes that alcohol co-ingestion is documented to increase the risk of stomach bleeding. Furthermore, the interaction risk is officially noted as greater in elderly patients and those with altered renal function.

Mechanism of Action

Inhibition of the Cyclooxygenase (COX) Enzyme

Etodolac's primary action is the suppression of the cyclooxygenase (COX) enzyme, which functions as a key component in the arachidonic acid cascade. By blocking the active site of COX, the compound limits the biosynthesis of lipid mediators known as prostaglandins. This targeted enzyme interference initiates the fundamental dampening of excessive signaling that drives the physiological inflammatory response.

Preferential Modulation of COX-2

The compound exhibits preferential selectivity for the COX-2 isoform, the enzyme primarily induced in affected tissues. This focuses the compound’s mechanistic activity on the pathways responsible for heightened physiological responses. By acting mainly on COX-2, this action influences a shift toward a modulated state which results in the reduction of excessive mediator activity associated with the disease process.

Modulation of Prostaglandin-Mediated Effects

The overall mechanistic cascade leads to a reduction in the systemic and localized levels of pro-inflammatory prostaglandins. This mechanism directly modulates overactive physiological responses. The reduced mediator availability results in changes within the sensory and vascular systems. This activity reflects the compound's influence on the sensory and vascular aspects of inflammation.

Dosage and Administration Information

How to Use Etodol: Official Administration Guidelines

Etodolac (Etodol) is administered exclusively through the oral route, available as both immediate-release (IR) tablets/capsules and extended-release (ER) tablets. Standard guidelines establish precise regimens that prioritize the use of the lowest effective dose for the shortest duration.

Standard Adult Dosing and Frequency

Formulation Dosing Range Frequency Maximum Daily Dose (Example)
IR Tablets/Capsules 600 mg to 1000 mg Divided doses (e.g., two to three times daily) 1000 mg or 1200 mg
ER Tablets 400 mg to 1000 mg Once daily 1200 mg

For acute pain, the IR form is typically administered as 200 mg to 400 mg every six to eight hours. For chronic conditions such as Osteoarthritis or Rheumatoid Arthritis, the maintenance dose may start as low as 600 mg per day.

Administration Requirements and Special Populations

Contextual Intake: The medicine can be taken with or without food, although consuming it with food or a full glass of water is common practice. For potentially faster absorption when using the IR form for acute effects, the dose may be taken 30 minutes before or 2 hours after meals.

Handling: Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed, as this alters the designed delivery of the medicine. If a dose is missed, the standard procedure is to resume the next dose at the scheduled time without attempting to double the amount.

Population Adaptations: Specific, weight-based dosing is established for the ER tablet when used in pediatric patients between 6 and 16 years of age. Generally, no mandatory dosage adjustment is required solely for older adults or for individuals with mild-to-moderate renal or hepatic dysfunction.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etodol

Evidence for Use in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

The primary body of research for Etodolac was studied for conditions such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). This evidence involves short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. In both OA and RA studies, research monitored patient-reported outcomes describing physical discomfort and evaluated changes measured in pain intensity and daily functioning.

The findings describe patterns observed in the studies where the symptomatic changes measured were observed in the research contexts. The core evidence level is generally rated as high due to the volume of controlled trials available. However, the evidence remains focused on symptomatic outcomes, and studies provide limited data for long-term physiological outcomes or monitoring of any potential changes to disease progression itself.

Research Evidence in Acute Pain

Research exploring Etodolac was studied for short-term or episodic symptom patterns, such as pain following medical or dental procedures, and primarily relies on single-dose, placebo-controlled trials. These studies focused on episodes where symptoms become more noticeable and explored short-term symptom changes immediately following a single dose.

Studies monitored outcomes linked to inflammatory or irritative states, such as pain intensity, and recorded the time until patients needed to use a supplementary pain reliever. Research describes patterns where the measured changes in discomfort were observed in the studies and compared to the patterns recorded for placebo groups.

A key limitation of this research is its very short-term duration, as studies explored symptom patterns immediately following a single event. The evidence mainly applies to temporary physiological imbalance and acute, disruptive episodes.

Studies in Special Populations and Pediatrics

Research has also explored Etodolac in certain special populations, including older adults and children with Juvenile Rheumatoid Arthritis (JRA). In older adults, the evidence describes that studies examined how the body processed the medicine. For children and adolescents (ages 6 to 16) with JRA, Etodolac was evaluated in open-label trials focused primarily on pharmacokinetic analysis (studies that measure how the drug moves through the body). The research base contains insufficient data for children under the age of six.

Frequently Asked Questions (FAQ)

Common questions about Etodol (FAQ)

Q: Is Etodol the same as other pain relief medications I can buy?

A: Etodolac, the active ingredient in this medicine, is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is primarily used to manage inflammation and pain associated with specific conditions, such as arthritis and acute pain. Unlike some over-the-counter NSAIDs, Etodol is only available via prescription.

Q: How long does it typically take before Etodol starts working?

A: Official information regarding the medicine’s absorption indicates that the highest concentrations in the bloodstream are typically reached in approximately 80 minutes after taking a dose. For chronic conditions like arthritis, the full symptomatic response observed in studies is usually noted within one to two weeks.

Q: Is it okay to take Etodol on an empty stomach?

A: Official labeling for this medicine states that it can be taken with or without food. Official guidance notes that consuming it with food may be common practice and may assist in reducing the incidence of stomach upset or discomfort.

Q: Does Etodol make you feel sleepy or drowsy?

A: Regulatory documents list central nervous system effects such as fatigue and dizziness among the commonly documented side effects. Some official sources also mention somnolence, which is the medical term for drowsiness, as a possible effect.

Q: Can I take Etodol if I have kidney issues?

A: Official labeling states that the medicine is contraindicated, or prohibited, for use in patients with advanced renal disease (severe kidney problems). For patients with mild to moderate kidney dysfunction, official documents require careful monitoring. Patients are generally advised to discuss all pre-existing conditions with a healthcare professional.

Q: What happens if you take Etodol too close to another dose?

A: Official dosing guidelines establish specific time intervals between doses and define a maximum daily dose. Taking doses too close together may risk exceeding the maximum allowed amount, which could potentially increase the likelihood of adverse effects.

Q: Are there any official warnings about Etodol and heart health?

A: Yes, official labeling includes a Boxed Warning regarding the class of medicine. This warning states that it may increase the risk of serious cardiovascular thrombotic events, which include outcomes such as a heart attack (myocardial infarction) and stroke. This risk may increase with the duration of use.

Q: Why do official documents mention 'risk of bleeding' with Etodol?

A: The risk is a result of the medicine's mechanism as an NSAID, which works by affecting certain processes in the body, including those that regulate blood clotting (platelet aggregation). This action can lead to serious gastrointestinal events like bleeding or perforation, as detailed in regulatory documents.

Q: Is Etodol safe for people with asthma?

A: The medicine is contraindicated (prohibited) for use in patients who have a history of experiencing asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs. Patients are generally advised to discuss all pre-existing conditions with a healthcare professional.

Q: How is Etodol eliminated from the body?

A: According to official product information, the medicine is extensively processed in the liver. The resulting compounds are then primarily eliminated from the body through renal excretion (excreted via the kidneys) and partially through feces.

Q: Can Etodol be taken by older adults?

A: Official labeling notes that the drug is approved for adult use. However, older patients are identified as a population at a greater risk for serious gastrointestinal and cardiovascular events. Official guidance requires caution and monitoring when prescribing to this age group.

Q: Does Etodol contain ibuprofen or aspirin?

A: The sole active ingredient in this medicine is Etodolac. However, due to the increased risk of gastrointestinal side effects, official warnings caution against using Etodol concurrently with other NSAIDs (such as ibuprofen) or non-low-dose aspirin.

Q: Can Etodol be used just for headaches?

A: The medicine is officially indicated for the management of acute pain. While headache is a type of acute pain, the official indications do not list headache as a specific condition of use.

Q: Are there any common foods or drinks that interact with Etodol?

A: Official labeling specifically notes that the co-ingestion of alcohol is documented to increase the risk of stomach bleeding. No other common foods or drinks are listed as having specific interactions that alter the drug's effects.

Q: How long does the effect of one dose of Etodol last?

A: The duration of effect for the immediate-release form is linked to the standard dosing frequency of every six to eight hours. Studies on the conventional form observed an analgesic duration of typically 5 to 6 hours.

Q: Are there any herbal supplements that interact with Etodol?

A: Official patient warnings advise disclosing all medications, vitamins, or herbal supplements taken. Official warnings note that certain supplements may affect blood clotting or alter the medicine's effects, and patients are advised to disclose all substances used.

Q: What is the earliest age someone can take Etodol?

A: The earliest age of approved use is 6 years old. This is specifically for the extended-release formulation to treat Juvenile Rheumatoid Arthritis, and its administration requires weight-based dosing.

Q: Can Etodol be split or crushed to make it easier to swallow?

A: Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed. However, official patient guides indicate that immediate-release tablets may be cut or crushed to assist with swallowing.

Q: Are there specific times of day that are better to take Etodol?

A: Official guidance for the immediate-release form, when used for fast-acting effects, notes it may be taken 30 minutes before or 2 hours after meals for potentially quicker absorption. Extended-release tablets are generally taken once daily, which is often done at the same time each day.

Q: Can Etodol affect my ability to drive or operate machinery?

A: Side effects commonly reported in official documentation, such as dizziness and fatigue, may affect coordination and concentration. Patients should observe how they react to the medicine before engaging in complex tasks, as required alertness may be affected by these reported side effects.

Q: Is it safe to take Etodol with antacids?

A: Studies show that taking the medicine with an antacid does not affect the overall absorption of the drug. However, official product information indicates that it may slightly decrease the peak concentration reached in the bloodstream by a small percentage.

Q: Can Etodol be used during the first few days of a menstrual cycle?

A: The medicine is officially indicated for the management of acute pain. While use during the menstrual cycle is not prohibited, official documents state that the medicine is not recommended for women attempting to conceive and is contraindicated (prohibited) in the third trimester of pregnancy.

Q: Does Etodol interact with vitamins like Vitamin D or B12?

A: Official patient warnings advise disclosing all medications, vitamins, or herbal supplements taken. While specific vitamins like D or B12 are not listed as having documented interactions in the professional label, patients are generally advised to disclose all substances used.

Q: Can Etodol be taken by people who are lactose intolerant?

A: Certain formulations, specifically the capsules, list lactose monohydrate as an inactive ingredient. Patients with lactose intolerance may wish to review the inactive ingredient list with a healthcare professional.

Q: Can Etodol be used for back pain relief?

A: The medicine is officially indicated for the management of acute pain and pain from chronic conditions like osteoarthritis and rheumatoid arthritis. Back pain is not listed as a specific indication but may be covered under these general uses.

Q: Can Etodol cause changes in appetite?

A: Loss of appetite has been listed as a possible side effect of the medicine in official safety documentation. Patients experiencing changes in appetite may wish to discuss this symptom with a healthcare professional.

Q: What is the significance of the research evidence for Etodol?

A: The clinical research evidence, which includes controlled trials and systematic reviews, provides the necessary data to support the medicine’s official uses. This evidence dictates the conditions for which the medicine is indicated, such as osteoarthritis, rheumatoid arthritis, and acute pain.

How should Etodol be stored and disposed of?

How to Store and Dispose of Etodolac

Etodolac must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from freezing, excessive heat, and moisture to maintain stability.

Storage and Handling

Requirement Official Regulatory Condition
Temperature Controlled Room Temperature, protected from freezing.
Container Keep in a tightly closed container; immediate-release tablets require a light-resistant container.
Child Safety Mandatory to keep out of the reach of children.

Disposal

Unused or expired product should be disposed of by utilizing an authorized drug take-back program. If a take-back option is unavailable, the medicine must be removed from its original container, mixed with an undesirable substance (e.g., dirt or coffee grounds), and sealed in a container before discarding it in the household trash. Personal information on the prescription label must be obscured prior to discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Etodol found in:

A-Z Index: